CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic

Frontiers in Oncology

Volumn 4, Issue , 2015, Pages

  Callahan, Margaret K ^a,b   Postow, Michael A ^a,b   Wolchok, Jedd D ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

CLTA 4; immunotherapy; ipilimumab; nivolumab; PD 1

Indexed keywords

EID: 85119037788     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00385     Document Type: Review

References (38)

1. Walunas TL Lenschow DJ Bakker CY Linsley PS Freeman GJ Green JM et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity (1994) 1:405–13.10.1016/1074-7613(94)90071-X7882171
2. Green JM Noel PJ Sperling AI Walunas TL Gray GS Bluestone JA et al. Absence of B7-dependent responses in CD28-deficient mice. Immunity (1994) 1:501–8.10.1016/1074-7613(94)90092-27534617
3. Krummel MF Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med (1995) 182:459–65.10.1084/jem.182.2.4597543139
4. Leach DR Krummel MF Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 271:1734–6.10.1126/science.271.5256.17348596936
5. Grosso JF Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun (2013) 13:5. Available frpm: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3559193/23390376
6. Intlekofer AM Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol (2013) 94:25–39.10.1189/jlb.1212621
7. Callahan MK Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol (2013) 94:41–53.10.1189/jlb.1212631
8. Hodi FS O’Day SJ McDermott DF Weber RW Sosman JA Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 363:711–23.10.1056/NEJMoa1003466
9. Robert C Thomas L Bondarenko I O’Day S Weber J Garbe C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 364:2517–26.10.1056/NEJMoa110462121639810
10. Keir ME Butte MJ Freeman GJ Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 26:677–704.10.1146/annurev.immunol.26.021607.09033118173375
11. Topalian SL Hodi FS Brahmer JR Gettinger SN Smith DC McDermott DF et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 366:2443–54.10.1056/NEJMoa120069022658127
12. Hodi FS. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. J Clin Oncol (2014) 32(5s):abstr9002. Available from: http://meetinglibrary.asco.org/content/125578-144
13. Hamid O Robert C Daud A Hodi FS Hwu WJ Kefford R et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 369:134–44.10.1056/NEJMoa130513323724846
14. Hamanishi J. Efficacy and safety of anti-PD-1 antibody (nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer. ASCO Annual Meeting 2014. (2014) 32(5s):abstr5511. Available from: http://meetinglibrary.asco.org/content/130814-144
15. Motzer R. Nivolumab for metastatic renal cell carcinoma (mRCC): results of a randomized, dose-ranging phase II trial. J Clin Oncol (2014) 32(5s):abstr5009. Available from: http://meetinglibrary.asco.org/content/125893-144
16. Gandhi LBA Hui R et al. MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): antitumor activity and association with tumor PD-L1 expression. American Association for Cancer Research Annual Meeting 2014. San Diego, CA (2014). Abstr CT105 2014.
17. Rizvi N. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol (2014) 32(5s):abstr8007. Available from: http://meetinglibrary.asco.org/content/132675-144
18. Ribas A Hodi F Kefford R Hamid O Adil Daud JDW Wen-Jen H et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J Clin Oncol (2014) 32(5s):abstrLBA9000. Available from: http://meetinglibrary.asco.org/content/133842-144
19. Seiwert T Burtness B Weiss J Iris Gluck JPE Sara IP Marisa DF et al. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer. J Clin Oncol (2014) 32(5s):abstr6011. Available from: http://meetinglibrary.asco.org/content/132361-144
20. Robert C Long GV Brady B Dutriaux C Maio M Mortier L et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014).10.1056/NEJMoa141208225399552
21. Robert C Ribas A Wolchok JD Hodi FS Hamid O Kefford R et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (2014) 384:1109–17.10.1016/S0140-6736(14)60958-225034862
22. Brahmer JR Tykodi SS Chow LQ Hwu WJ Topalian SL Hwu P et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 366:2455–65.10.1056/NEJMoa120069422658128
23. Herbst R Gordon M Fine G Sosman J Jean-Charles Soria OH John D et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J Clin Oncol (2013) 31:abstr3000. Available from: http://meetinglibrary.asco.org/content/115865-132
24. Hamid O Sosman J Lawrence D Sullivan R Nageatte Ibrahim HMK Peter D et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J Clin Oncol (2013) 31:abstr9010. Available from: http://meetinglibrary.asco.org/content/115916-132
25. Soria J Cruz C Bahleda R et al. Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC). Eur Cancer Cong (2013). Abstract3408. Available from: http://2013.europeancancercongress.org/Scientific-Programme/Abstract-search?abstractid=6899
26. Powles T Vogelzang N Fine G Eder J Fadi S Braiteh YL et al. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). J Clin Oncol (2014) 32(5s):abstr5011. Available from: http://meetinglibrary.asco.org/content/128960-144
27. Segal N Antonia S Brahmer J Michele Maio AB-H Xia L Jim V et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. J Clin Oncol (2014) 32(5s):abstr3002. Available from: http://meetinglibrary.asco.org/content/134136-144
28. Korman A Chen B Wang C Wu L Cardarelli P Selby M. Activity of anti-PD-1 in murine tumor models: role of “host” PD-L1 and synergistic effect of anti-PD-1 and anti-CTLA-4. J Immunol (2007) 178:S82. Available from: http://www.jimmunol.org/cgi/content/meeting_abstract/178/MeetingAbstracts/S82
29. Curran MA Montalvo W Yagita H Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 107:4275–80.10.1073/pnas.091517410720160101
30. Wolchok JD Kluger H Callahan MK Postow MA Rizvi NA Lesokhin AM et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 369:122–33.10.1056/NEJMoa130236923724867
31. Sznol M. Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol (2014) 31:abstractCRA9006.
32. Sznol M Kluger H Hodi F David F McDermott RDC Donald P et al. Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol (2013) 31:abstrCRA9006.
33. Weber JS Kudchadkar RR Yu B Gallenstein D Horak CE Inzunza HD et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol (2013) 31:4311–8.10.1200/JCO.2013.51.480224145345
34. Brahmer JR Drake CG Wollner I Powderly JD Picus J Sharfman WH et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 28:3167–75.10.1200/JCO.2009.26.760920516446
35. Callahan MK. Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab. J Clin Oncol (2013) 31:abstr3003.
36. Callahan M Horak C Curran M Travis Hollman DAS Jianda Y Alexander M et al. Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab. J Clin Oncol (2013) 31:abstr3003.
37. Hammers H. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J Clin Oncol (2014) 32(5s):abstr4504.
38. Antonia S. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results. J Clin Oncol (2014) 32(5s):abstr8023.